Search results
Showing 1096 to 1110 of 2026 results for nice guidelines
Awaiting development Reference number: GID-TA11907 Expected publication date: 10 June 2027
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on olaparib (Lynparza) for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy in adults.
View recommendations for TA1040Show all sections
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
Discontinued Reference number: GID-NG10053
Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.
Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.
Discontinued Reference number: GID-NG10377
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Discontinued Reference number: GID-NG10387
Discontinued Reference number: GID-NG10289
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .